Satellos Bioscience Inc.
MSLENext catalyst
SAT-3247
Duchenne Muscular Dystrophy
Get an email about MSLE's next catalysts
Track Satellos Bioscience (MSLE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
MSLE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.44 | FQ end Sep/2026 | Call: tbd
SAT-3247 Phase 2 Est. Readout (BASECAMP)
Primary completion for SAT-3247 trial (NCT07287189) in Duchenne Muscular Dystrophy
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Frequently asked questions
What is in Satellos Bioscience Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Satellos Bioscience Inc.'s (MSLE) pipeline across Phase 2. Its lead program is SAT-3247 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Satellos Bioscience Inc.'s next FDA catalyst?→
Satellos Bioscience Inc.'s (MSLE) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MSLE biotech catalysts?→
Add MSLE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Satellos Bioscience Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.